Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment.
Two different treatments with repeated oral high doses of itraconazole were tested for 10 days in 20 neutropenic patients, 10 receiving 400 mg per day and 10 receiving 600 mg per day. In each group 5 patients were treated for acute leukaemia and 5 patients were recipients of autologous bone-marrow transplantation (ABMT). Itraconazole plasma concentrations were assayed by high-performance liquid chromatography. Statistical analysis disclosed a significant interaction between the dispensed dose and the patient types. The difference between the two doses of itraconazole was greater in the ABMT than in the leukaemia patients. After 10 days at 600 mg per day all the ABMT patients had an itraconazole plasma concentration higher than 250 micrograms/l. Therefore, 600 mg per day seems more efficient to obtain a therapeutic level of itraconazole in ABMT patients but this needs to be confirmed for all the neutropenic patients.
Persat
F
F
Département de Parasitologie et de Mycologie, Université Claude Bernard Lyon, France.
Marzullo
C
C
Guyotat
D
D
Rochet
M J
MJ
Piens
M A
MA
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000097:blood; D007938:Leukemia / Q000188:drug therapy / Q000601:surgery; D008875:Middle Aged; D009503:Neutropenia / Q000097:blood* / Q000139:chemically induced
D000970:Antineoplastic Agents; D017964:Itraconazole; D007654:Ketoconazole